Published in Eur J Clin Pharmacol on June 15, 2017
A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition (1992) 16.89
Long-term efficacy and safety of cyclosporine in renal-transplant recipients. N Engl J Med (1994) 2.93
The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev (1984) 1.61
Metabolism of cyclosporine. Transplant Proc (1985) 1.57
The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet (1991) 1.44
Resting metabolic rate, weight, surface area and body composition in obese women. Int J Obes (1979) 1.27
Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation (1988) 1.26
Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. N Engl J Med (1988) 1.23
The clinical benefits of cyclosporine C2-level monitoring: a systematic review. Transplantation (2007) 1.17
Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet (1993) 1.16
Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet (1992) 1.07
Relationships among liver and kidney volumes, lean body mass and drug clearance. Br J Clin Pharmacol (1998) 1.03
Pharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozocin: comparison with those in patients with type I diabetes mellitus. J Pharm Pharmacol (2010) 0.99
Tissue distribution, disposition, and metabolism of cyclosporine in rats. Drug Metab Dispos (1987) 0.92
Cyclosporine-induced renal dysfunction in experimental animals and humans. Kidney Int Suppl (1995) 0.92
Population pharmacokinetics of cyclosporine in clinical renal transplant patients. Drug Metab Dispos (2005) 0.91
Comparison of several approaches of therapeutic drug monitoring of cyclosporin A based on individual pharmacokinetics. Eur J Clin Pharmacol (2000) 0.84
Effect of contrast injection protocols with dose adjusted to the estimated lean patient body weight on aortic enhancement at CT angiography. AJR Am J Roentgenol (2009) 0.83
Effect of body surface area calculations on body fat estimates in non-obese and obese subjects. Physiol Meas (2006) 0.83
Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients. Eur J Clin Pharmacol (2010) 0.81
Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients. Ther Drug Monit (2007) 0.81
Influence of intravenous methylprednisolone pulse treatment on the disposition of ciclosporin and hepatic CYP3A activity in rats. J Pharm Pharmacol (2004) 0.80
Population pharmacokinetic study of cyclosporine in the hematopoietic stem cell transplant recipients. Int J Clin Pharmacol Ther (2013) 0.80
Improving tolerability of immunosuppressive regimens. Transplantation (2001) 0.80
Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine--results at 24 months after transplantation. Transplantation (2001) 0.79
C2 versus C0 cyclosporine monitoring: still not the end. Transplantation (2005) 0.79
Population pharmacokinetics of cyclosporine in transplant recipients. AAPS J (2013) 0.79
Explaining variability in ciclosporin exposure in adult kidney transplant recipients. Eur J Clin Pharmacol (2010) 0.79
Altered intestinal P-glycoprotein expression levels in a monosodium glutamate-induced obese mouse model. Life Sci (2011) 0.79
Dose adjustment strategy of cyclosporine A in renal transplant patients: evaluation of anthropometric parameters for dose adjustment and C0 vs. C2 monitoring in Japan, 2001-2010. Int J Med Sci (2013) 0.78
[Neoral (Cyclosporin microemulsion preconcentrate): pharmacokinetics, pharmacodynamics and its improved clinical outcome]. Nihon Yakurigaku Zasshi (2001) 0.77
Pharmacokinetic-Pharmacodynamic Analysis of Cisplatin with Hydration and Mannitol Diuresis: The Contribution of Urine Cisplatin Concentration to Nephrotoxicity. Eur J Drug Metab Pharmacokinet (2017) 0.75